Author holds 60,000 shares of ADXT, arguing the SPAC merger with Ignite Proteomics is undervalued relative to the proteomics market and could pay off debt, while warning of delisting risk below $0.10.
ADXT — LONG The author is long ADXT with 60,000 shares, arguing the SPAC merger that pays ADXT $150 million in shares for Ignite Proteomics going independent would be very bullish at the current ~$13k market cap. A more conservative $30 million valuation could pay off debt and cover $11 million in liabilities, leaving the rest as assets, and Ignite's innovative protein-pathway tumor detection technology targets a proteomics market the author cites as over $39 billion. The main stated risk is that if the stock does not get above $0.10, a delisting notice will be sent.
In all fairness, this spac merger pays $ADXT with $150 million in shares for Ignite Proteomics moving to be independent and would be very bullish at its current market cap of only $13k.
This Reddit post, published June 15, 2026, features u/Jazzlike_Rhubarb4639 discussing ADTX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Jazzlike_Rhubarb4639 · Tickers: ADTX